



NDA 204063/S-009

SUPPLEMENT APPROVAL

Biogen Idec
Attention: Nadine D. Cohen, Ph.D.
Senior Vice President, Regulatory Affairs
14 Cambridge Center
Cambridge, MA 02142

Dear Dr. Cohen:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 14, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tecfidera (dimethyl fumarate) Tablets, 120 mg and 240 mg .

This “Prior Approval” supplemental new drug application provides for Biogen’s response to the Agency’s recommendations made during a previous postmarketing review for revised container labels for Tecfidera 30-day Starter Pack.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 204063/S-009. Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Laurie Kelley, PA-C, Regulatory Project Manager, via telephone at (301) 796-5068 or via email at Laurie.Kelley@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Eric Bastings, M.D.
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
11/14/2014